About PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics (EPA:PHXM), (NASDAQ:PHXM) pioneers cutting-edge solutions in pharmaceuticals, focused on transforming lives through innovative therapies. Specializing in precision medicine, PHAXIAM harnesses the power of advanced technologies and deep scientific expertise to develop targeted treatments for challenging diseases. With a commitment to patient-centric care, the company strives for breakthroughs in areas such as oncology, immunology, and rare genetic disorders. PHAXIAM's robust pipeline is propelled by a culture of collaboration, drawing on interdisciplinary insights to drive impactful advancements in healthcare. Positioned at the forefront of therapeutic innovation, PHAXIAM Therapeutics is dedicated to shaping a healthier future for global communities.

Snapshot

2004Year founded

92Employees

Lyon, FranceHead office

Loading Map...

Global footprint

Operations

All Locations

Republic of France

Products and/or services of PHAXIAM Therapeutics S.A.

Precision Oncology Therapies: PHAXIAM Therapeutics specializes in developing precision oncology therapies tailored to individual patient profiles, aiming to revolutionize cancer treatment and improve patient outcomes.
Immunomodulatory Drugs: PHAXIAM's immunomodulatory drugs target the immune system, offering novel approaches to treating autoimmune diseases, inflammatory disorders, and other conditions where immune responses play a central role.
Rare Disease Treatments: PHAXIAM is dedicated to addressing the unmet needs of patients with rare genetic disorders by developing innovative therapies that target the underlying molecular mechanisms of these conditions.
Personalized Medicine Platforms: PHAXIAM leverages advanced personalized medicine platforms to identify biomarkers, predict treatment responses, and tailor therapies to individual patients, optimizing efficacy and minimizing side effects.
Therapeutic Antibodies: The company's portfolio includes therapeutic antibodies designed to selectively target disease-associated antigens, offering precise and potent treatment options across a range of therapeutic areas.
Clinical Research Services: PHAXIAM provides comprehensive clinical research services, including study design, patient recruitment, data analysis, and regulatory support, to advance the development of novel therapeutics from early-stage research through to market approval.

PHAXIAM Therapeutics S.A. executive team

Mr. Eric Soyer Ph.D.Deputy CEO, Deputy GM, CFO & COO
Dr. Jérôme Bailly Pharm.D.Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person
Mr. Thibaut du FayetChief Executive Officer
Ms. Céline BredaChief Technology Officer
Ms. Cindy FevreChief Scientific Officer
Naomi EichenbaumDirector Investor Relations
Ms. Anne-Cécile FumeyVice President of Human Resources
Ms. Karine Charton Ph.D.Chief Business Officer
Dr. Pascal Birman M.D.Chief Medical Officer
Ms. Frederique VievilleChief Regulatory Officer

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift